Join
Live feed
·
PRReleasevia Quantisnow
MaxCyte Inc. logo

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

ByQuantisnow·Wall Street's wire, on your screen.
MXCT· MaxCyte Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MXCT (MaxCyte Inc.) and more on Quantisnow.